How do you choose a second-line treatment option for depression?

Journal of Clinical Psychiatry

Volumn 71, Issue SUPPL. 1, 2010, Pages 21-26

  Weisler, Richard H ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; APLENZIN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE MESILATE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LAMOTRIGINE; LEVO T; LEVOTHYROXINE SODIUM; LIOTHYRONINE; LITHIUM CARBONATE; MAPROTILINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; OLEPTRO; PAROXETINE; PHENELZINE; PROTRIPTYLINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; REBOXETINE; RISPERIDONE; SAVELLA; SELEGILINE; SERTRALINE; THYROXINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; HUMAN; MAJOR DEPRESSION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REMISSION; REVIEW; STROKE; SUICIDE ATTEMPT; SYMPTOM; TREATMENT REFUSAL;

ANTIDEPRESSIVE AGENTS; BEHAVIORAL SYMPTOMS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 78149337538     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.9104su1c.04     Document Type: Review

References (30)

1. National Association of State Mental Health Program Directors. Morbidity and Mortality in People with Serious Mental Illness. Technical Reports. Alexandria, VA: National Association of State Mental Health Program Directors Medical Directors Council; 2006.
2. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739-752. doi:10.176/api.ajp. 164.5.739 PubMed
3. McIntyre RS. When should you move beyond first-line therapy for depression? J Clin Psychiatry. 2010;71(suppl 1):16-20.
4. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161-174. doi:10.408/JCP.v64n0209 PubMed
5. Akiskal HS, Walker P, Puzantian VR, et al. Bipolar outcome in the course of depressive illness: phenomenologic, familial, and pharmacologic predictors. J Affect Disord. 1983;5(2):115-128. doi:10.1016/0165-0327(83)904-6 PubMed (Pubitemid 13120405)
6. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67-74. doi:10.1097/05650-195010-06 PubMed
7. Suehs BT, Argo TR, Bendele SD, et al. Texas Medication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms. Austin, TX: Texas Department of State Health Services; 2008.
8. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009;70(suppl 5):12-17. doi:10.408/JCP.8157su1c.03 PubMed
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
10. Deisenhammer EA, Ing CM, Strauss R, et al. The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt? J Clin Psychiatry. 2009;70(1):19-24. doi:10.408/JCP.07m03904 PubMed
11. Guzzetta F, Tondo L, Centorrino F, et al. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68(3):380-383. doi:10.408/JCP.v68n0304 PubMed
12. Cole J, Toga AW, Hojatkashani C, et al. Subregional hippocampal deformations in major depressive disorder. J Affect Disord. 2010;126(1-2):272- 277. doi:10.1016/j.jad.2010.03.04 PubMed
13. Hippisley-Cox J, Fielding K, Pringle M. Depression as a risk factor for ischaemic heart disease in men: population based case-control study. BMJ. 1998;316(7146):1714-1719. PubMed
14. Lespérance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med. 1996;58(2):99-110. PubMed
15. Lespérance F, Frasure-Smith N, Talajic M, et al. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002;105(9):1049-1053. doi:10.161/hc0902.104707 PubMed
16. Penninx BW, Beekman AT, Honig AT, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58(3):221-227. doi:10.101/archpsyc.58.3.21 PubMed
17. Jiang W, O'Connor C, Silva SG, et al. Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, doubleblind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J. 2008;156(3):437-444. doi:10.1016/j.ahj.208.05.03 PubMed
18. Starkstein SE, Mizrahi R, Power BD. Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother. 2008;9(8):1291-1298. doi:10.1517/1465656. 9.8.1291 PubMed
19. Parikh RM, Robinson RG, Lipsey JR, et al. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol. 1990;47(7):785-789. PubMed
20. Jorge RE, Acion L, Moser D, et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010;67(2):187-196. doi:10.101/archgenpsychiatry.209.185 PubMed
21. Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. http://www.cdc.gov/HomeandRecreationalSafety/Poisoning/ brief.htm. Published March 18, 2010. Accessed September 14, 2010.
22. Paulozzi LJ, Weisler RH, Patkar AA. Unintentional drug poisoning deaths: a national epidemic. http://www.medscape.com/viewarticle/724186. Published June 28, 2010. Accessed September 14, 2010.
23. Mohr P, Bitter I, Svestka J, et al. Management of depression in the presence of pain symptoms. Psychiatr Danub. 2010;22(1):4-13. PubMed
24. Office of Diversion Control, Drug Enforcement Administration, US Dept of Justice. Questions and answers: state prescription drug monitoring programs. http://www.deadiversion.usdoj.gov/faq/rx-monitor.htm. Updated July 2010. Accessed July 31, 2010.
25. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67-85. doi:10.1097/04714- 19020-013 PubMed
26. Demyttenaere K, Jaspers L. Review: Bupropion and SSRI-induced side effects. J Psychopharmacol. 2008;22(7):792-804. doi:10.17/02698107083798 PubMed
27. Westheide J, Cvetanovska G, Albrecht C, et al. Prolactin, subjective wellbeing and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med. 2008;5(12):2816-2826. doi:10.1/j.1743-6109.208.0859.x PubMed
28. Landén M, Eriksson E, Agren H, et al. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19(3):268-271. doi:10.1097/04714-19060-012 PubMed
29. Rush AJ, Trivedi MH, Wisniewski SR, et al, for the STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242. doi:10.1056/NEJMoa052963 PubMed
30. Trivedi MH, Fava M, Wisniewski SR, et al, for the STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252. doi:10.1056/NEJMoa052964 PubMed